Skip to main content

Keveyis Disease Interactions

There are 9 disease interactions with Keveyis (dichlorphenamide).

Major

Dichlorphenamide (applies to Keveyis) acidosis

Major Potential Hazard, Moderate plausibility.

The use of dichlorphenamide is contraindicated acidotic patients (hyperchloremic or respiratory).

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Major

Dichlorphenamide (applies to Keveyis) adrenocortical insufficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency

The use of dichlorphenamide is contraindicated in adrenocortical insufficiency.

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Major

Dichlorphenamide (applies to Keveyis) dehydration

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypokalemia, Hyponatremia

The use of dichlorphenamide is contraindicated in patients with hyponatremia or hypokalemia, or in conditions in which serum levels of sodium or potassium are depressed.

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Major

Dichlorphenamide (applies to Keveyis) hepatic disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of dichlorphenamide is contraindicated in hepatic insufficiency.

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Major

Dichlorphenamide (applies to Keveyis) pulmonary disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

Dichlorphenamide should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation as their acidosis may be increased.

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Major

Dichlorphenamide (applies to Keveyis) renal dysfunction

Major Potential Hazard, Moderate plausibility.

The use of dichlorphenamide is contraindicated in renal failure.

References

  1. "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Moderate

Carbonic anhydr. inhibitors (applies to Keveyis) respiratory acidosis

Moderate Potential Hazard, Low plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.

References

  1. Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63
  2. Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
  3. "Product Information. Diamox (acetazolamide)." Lederle Laboratories PROD (2001):
  4. "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
View all 4 references
Moderate

Carbonic anhydrase inhibitors (applies to Keveyis) diabetes mellitus

Moderate Potential Hazard, Low plausibility.

Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.

References

  1. Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991): 457-64
  2. Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
  3. "Product Information. Diamox (acetazolamide)." Lederle Laboratories PROD (2001):
  4. "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
View all 4 references
Moderate

Carbonic anhydrase inhibitors (applies to Keveyis) gout

Moderate Potential Hazard, Moderate plausibility.

Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.

References

  1. Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969): 145-7
  2. "Product Information. Diamox (acetazolamide)." Lederle Laboratories PROD (2001):
  3. "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):

Keveyis drug interactions

There are 229 drug interactions with Keveyis (dichlorphenamide).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer